Oxidative Damage and Response to Bacillus Calmette-Guérin in Bladder Cancer Cells Expressing Sialyltransferase ST3GAL1

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2018 Feb 19

PMID 29454317

Citations 6

Authors

Paulo F Severino

Mariana Silva

Mylene Carrascal

Nadia Malagolini

Mariella Chiricolo

Giulia Venturi

Roberto Barbaro Forleo

Annalisa Astolfi

Mariangela Catera

Paula A Videira

Fabio DallOlio

Affiliations

Soon will be listed here.

Abstract

Background: Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of non-muscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumor-associated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in BCG response are unknown.

Methods: The human bladder cancer (BC) cell line HT1376 strongly expressing the T antigen, was retrovirally transduced with the ST3GAL1 cDNA or with an empty vector, yielding the cell lines HT1376 and HT1376, that express, respectively, either the sT or the T antigens. Cells were in vitro challenged with BCG. Whole gene expression was studied by microarray technology, cytokine secretion was measured by multiplex immune-beads assay. Human macrophages derived from blood monocytes were challenged with the secretome of BCG-challenged BC cells.

Results: The secretome from BCG-challenged HT1376 cells induced a stronger macrophage secretion of IL-6, IL-1β, TNFα and IL-10 than that of HT1376 cells. Transcriptomic analysis revealed that ST3GAL1 overexpression and T/sT replacement modulated hundreds of genes. Several genes preserving genomic stability were down-regulated in HT1376 cells which, as a consequence, displayed increased sensitivity to oxidative damage. After BCG challenge, the transcriptome of HT1376 cells showed higher susceptibility to BCG modulation than that of HT1376 cells.

Conclusions: High ST3GAL1 expression and T/sT replacement in BCG challenged-BC cancer cells induce a stronger macrophage response and alter the gene expression towards genomic instability, indicating a potential impact on BC biology and patient's response to BCG.

Citing Articles

Review of BCG immunotherapy for bladder cancer.

Liatsos G, Mariolis I, Hadziyannis E, Bamias A, Vassilopoulos D Clin Microbiol Rev. 2025; 38(1):e0019423.

PMID: 39932308 PMC: 11905372. DOI: 10.1128/cmr.00194-23.

Immune Predictors of Response after Bacillus Treatment in Non-Muscle-Invasive Bladder Cancer.

Rodriguez-Izquierdo M, Del Canizo C, Rubio C, Reina I, Hernandez Arroyo M, Rodriguez Antolin A Cancers (Basel). 2023; 15(23).

PMID: 38067259 PMC: 10705209. DOI: 10.3390/cancers15235554.

Altered Glycosylation in Progression and Management of Bladder Cancer.

Wilczak M, Surman M, PRZYBYlO M Molecules. 2023; 28(8).

PMID: 37110670 PMC: 10146225. DOI: 10.3390/molecules28083436.

Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment.

Nag S, Mandal A, Joshi A, Jain N, Srivastava R, Singh S Diseases. 2022; 10(4).

PMID: 36547200 PMC: 9777960. DOI: 10.3390/diseases10040114.

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.

Kong C, Zhang S, Lei Q, Wu S Biosensors (Basel). 2022; 12(10).

PMID: 36290934 PMC: 9599190. DOI: 10.3390/bios12100796.

References

Carretero R, Cabrera T, Gil H, Saenz-Lopez P, Maleno I, Aptsiauri N . Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer. 2010; 129(4):839-46. DOI: 10.1002/ijc.25733. View

Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J . A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn. 2001; 3(2):55-61. PMC: 1910699. DOI: 10.1016/S1525-1578(10)60652-6. View

Takeuchi H, Tanaka M, Tanaka A, Tsunemi A, Yamamoto H . Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness. Oncol Lett. 2016; 11(5):3403-3408. PMC: 4841030. DOI: 10.3892/ol.2016.4392. View

Kumar A, Dubey D, Bansal P, Mandhani A, Naik S . Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol. 2002; 168(5):2232-5. DOI: 10.1016/S0022-5347(05)64361-3. View

Chen F, Zhang G, Cao Y, Hessner M, See W . MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin. J Urol. 2009; 182(6):2932-7. DOI: 10.1016/j.juro.2009.08.018. View

Carrascal M, Severino P, Cabral M, Silva M, Ferreira J, Calais F . Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol. 2014; 8(3):753-65. PMC: 5528624. DOI: 10.1016/j.molonc.2014.02.008. View

Whitehouse C, Burchell J, Gschmeissner S, Brockhausen I, LLOYD K, Taylor-Papadimitriou J . A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J Cell Biol. 1997; 137(6):1229-41. PMC: 2132526. DOI: 10.1083/jcb.137.6.1229. View

Esuvaranathan K, Alexandroff A, McIntyre M, Jackson A, Prescott S, Chisholm G . Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol. 1995; 154(2 Pt 1):572-5. DOI: 10.1097/00005392-199508000-00072. View

Sheryka E, Wheeler M, Hausladen D, Weiss R . Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology. 2003; 62(1):162-6. DOI: 10.1016/s0090-4295(03)00134-1. View

10.

Videira P, Correia M, Malagolini N, Crespo H, Ligeiro D, Calais F . ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer. 2009; 9:357. PMC: 2763879. DOI: 10.1186/1471-2407-9-357. View

11.

Jackson A, Alexandroff A, Kelly R, Skibinska A, Esuvaranathan K, Prescott S . Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol. 1995; 99(3):369-75. PMC: 1534215. DOI: 10.1111/j.1365-2249.1995.tb05560.x. View

12.

Almogren A, Abdullah J, Ghapure K, Ferguson K, Glinsky V, Rittenhouse-Olson K . Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy. Front Biosci (Schol Ed). 2011; 4(3):840-63. DOI: 10.2741/s304. View

13.

Ferreira J, Videira P, Lima L, Pereira S, Silva M, Carrascal M . Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol Oncol. 2013; 7(3):719-31. PMC: 5528473. DOI: 10.1016/j.molonc.2013.03.001. View

14.

Engelstaedter V, Fluegel B, Kunze S, Mayr D, Friese K, Jeschke U . Expression of the carbohydrate tumour marker Sialyl Lewis A, Sialyl Lewis X, Lewis Y and Thomsen-Friedenreich antigen in normal squamous epithelium of the uterine cervix, cervical dysplasia and cervical cancer. Histol Histopathol. 2012; 27(4):507-14. DOI: 10.14670/HH-27.507. View

15.

Sagnak L, Ersoy H, Ozok U, Senturk B, Ercil H, Bahar G . Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer. 2009; 7(2):E16-23. DOI: 10.3816/CGC.2009.n.016. View

16.

DallOlio F, Malagolini N, Trinchera M, Chiricolo M . Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark Ed). 2011; 17(2):670-99. DOI: 10.2741/3951. View

17.

Ohyama C . Glycosylation in bladder cancer. Int J Clin Oncol. 2008; 13(4):308-13. DOI: 10.1007/s10147-008-0809-8. View

18.

Yang G, Tan Z, Lu W, Guo J, Yu H, Yu J . Quantitative glycome analysis of N-glycan patterns in bladder cancer vs normal bladder cells using an integrated strategy. J Proteome Res. 2014; 14(2):639-53. DOI: 10.1021/pr5006026. View

19.

Brockhausen I . Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999; 1473(1):67-95. DOI: 10.1016/s0304-4165(99)00170-1. View

20.

Burin des Roziers N, Chadebech P, Bodivit G, Guinchard E, Bruneel A, Dupre T . Red blood cell Thomsen-Friedenreich antigen expression and galectin-3 plasma concentrations in Streptococcus pneumoniae-associated hemolytic uremic syndrome and hemolytic anemia. Transfusion. 2015; 55(6 Pt 2):1563-71. DOI: 10.1111/trf.12981. View